

Breast Cancer

Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT02419742 ML28714

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This is a prospective, Phase IV, multi-center, single arm, open-label, interventional study to evaluate the safety of trastuzumab for the treatment of human epidermal growth factor receptor 2 protein (HER2)-positive node positive or high risk node negative breast cancer participants with regimen consisting of doxorubicin and cyclophosphamide followed by either paclitaxel or docetaxel (AC-TH Regimen) or a regimen consisting of docetaxel and carboplatin (TCH Regimen) in Indian population.

Hoffmann-La Roche
Sponsor

Phase 4
Phase

NCT02419742 ML28714
Trial Identifiers

Eligibility Criteria:

Gender
Female

Age
>= 18 Years

Healthy Volunteers
No
